检索结果-南通市图书馆

Futibatinib:new targeted therapy in intrahepatic cholangiocarcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatobiliary Surgery and Nutrition 2023年第6期12卷 923-926页

作者： Rita Khoury Nadine Khalife Rebecca Ibrahim Khalil Saleh International Department Gustave Roussy Cancer CampusVillejuifFrance Head and Neck Oncology Department Gustave Roussy Cancer CampusVillejuifFrance

Biliary tract tumors are a heterogenous group of cancers that includes extrahepatic cholangiocarcinoma,hilar cholangiocarcinoma,gallbladder tumor as well as intrahepatic cholangiocarcinoma(ICCA)(1).Biliary tract tumors are uncommon tumors representing 2%of all newly diagnosed cancers in the United *** incidence of ICCA is increasing worldwide and associated with a dismal prognosis,and the 5-year overall survival(OS)rate is not exceeding 8%(1).

关键词： Futibatinib RLY-4008 infigratinib pemigatinib cholangiocarcinoma

The PI3K/Akt/m TOR pathway in ovarian cancer: therapeutic opportunities and challenges

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of cancer 2015年第1期34卷 4-16页

作者： Bianca Cheaib Aurélie Auguste Alexandra Leary Gynecological Unit Department of MedicineGustave Roussy Comprehensive Cancer Centre Gynecological Tumor Team Translational Research Laboratory U981 Gustave Roussy Comprehensive Cancer Centre

The phosphatidylinositol 3 kinase(PI3K) pathway is frequently altered in cancer, including ovarian cancer(OC). Unfortunately, despite a sound biological rationale and encouraging activity in preclinical models, trials of first-generation inhibitors of mammalian target of rapamycin(m TOR) in OC have demonstrated negative results. The lack of patient selection as well as resistance to selective m TOR complex-1(m TORC1) inhibitors could explain the disappointing results thus far. Nonetheless, a number of novel agents are being investigated, including dual m TORC1/m TORC2, Akt, and PI3 K inhibitors. Although it is likely that inhibition of the PI3K/Akt/m TOR pathway may have little effect in unselected OC patients, certain histological types, such as clear cell or endometrioid OC with frequent phosphatidylinositol-4,5-biphosphate 3-kinase, catalytic subunit alpha(PIK3CA) and/or phosphatase and tensin homolog(PTEN) alterations, may be particularly suited to this approach. Given the complexity and redundancy of the PI3 K signaling network, PI3 K pathway inhibition may be most useful in combination with either chemotherapy or other targeted therapies, such as MEK inhibitors, anti-angiogenic therapy, and hormonal therapy, in appropriately selected OC patients. Here, we discuss the relevance of the PI3 K pathway in OC and provide an up-to-date review of clinical trials of novel PI3 K inhibitors alone or in combination with cytotoxics and novel therapies in OC. In addition, the challenges of drug resistance and predictive biomarkers are addressed.

关键词： mTOR 信号通路卵巢癌磷脂酰肌醇3激酶 AKT 激素疗法治疗临床试验

Antitumor efficacy of anti-CTLA4 antibody is dependant on gut microbiota.

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Antitumor efficacy of anti-CTLA4 antibody is dependant on gu...

Adenoma and advanced neoplasia detection rates increase from 45 years of age

第十届全国免疫学学术大会

作者： Marie Vetizou Jonathan M. Pitt Romain Daillère Laurence Zitvogel gustave roussy cancer campus INSERM U1015

The cytotoxic T lymphocyte antigen-4(CTLA-4)-blocking antibody ipilimumab is an FDA and EMEA-approved treatment for metastatic melanoma,which induces immune-mediated long-term control in 15%of ***,ipilimumab also results in substantial immune related side effects including grade III-IV *** uncouple efficacy and toxicity we analyzed the mode of action of anti-CTLA4 therapy in preclinical mouse ***,the gut microbiota was

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2019年第4期25卷 447-456页

作者： David Karsenti Gaelle Tharsis Pascal Burtin Franck Venezia Gilles Tordjman Agnès Gillet Joelle Samama Karine Nahon-Uzan Philippe Cattan Maryan Cavicchi Digestive Endoscopy Unit Clinique Paris-Bercy Digestive Endoscopy Unit Institut Gustave Roussy

BACKGROUND Colonoscopy is considered a valid primary screening tool for colorectal cancer(CRC). The decreasing risk of CRC observed in patients undergoing colonoscopy is correlated with the adenoma detection rate(ADR). Due to the fact that screening programs usually start from the age of 50, very few data are available on the risk of adenoma between 40 and 49 years. However, the incidence of CRC is increasing in young populations and it is not uncommon in routine practice to detect adenomas or even advanced neoplasia during colonoscopy in patients under 50 *** To compare the ADR and advanced neoplasia detection rate(ANDR) according to age in a large series of patients during routine *** All consecutive patients who were scheduled for colonoscopy were *** criteria were as follows: patients scheduled for partial colonoscopy or interventional colonoscopy(for stent insertion or stenosis dilation).Colonoscopies were performed in our unit by a team of 30 gastroenterologists in2016. We determined the ADR and ANDR in each age group in the whole population and in the population with an average risk of CRC(excluding patients with personal or family history of advanced adenoma or cancer).RESULTS6027 colonoscopies were performed in patients with a median age of 57 years(range, 15-96). The ADR and ANDR were 28.6% and 9.7%, respectively, in the whole population. When comparing patients aged 40-44(n = 382) and 45-49 years (n = 515), a strong increase in all parameters from 45 years was observed, with the ADR rising from 9.7% in patients aged 40-44 to 21.2% between 45 and 49(P <0.001) and the ANDR increasing from 3.1% in patients aged 40-44 to 6.4% in those aged 45-49 years(P < 0.03). With regard to patients aged 50-54(n = 849), a statistically significant increase in the ADR and ANDR was not observed between patients aged 45-49 and those aged 50-54 years. In the population with an average risk of CRC, the ADR and ANDR were still significantly h

关键词： Colorectal cancer Screening Adenoma detection rate Colonoscopy Cohort study

Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

cancer Drug Resistance 2021年第3期4卷 710-718页

作者： Jean-Marie Michot Alice Buet-Elfassy Maxime Annereau Julien Lazarovici Alina Danu Clémentine Sarkozy Claude Chahine Camille Bigenwald Jacques Bosq Julien Rossignol Patricia Romano-Martin Capucine Baldini David Ghez Peggy Dartigues Christophe Massard Vincent Ribrag gustave roussy UniversitéParis-SaclayDépartement des Innovations Thérapeutiques et Essais PrécocesVillejuif 94800France gustave roussy UniversitéParis-SaclayPharmacy DepartementVillejuif 94800France gustave roussy UniversitéParis-SaclayDepartement of HematologyVillejuif 94800France gustave roussy UniversitéParis-SaclayDepartement of PathologyVillejuif 94800France

Aim:Anti-CD20 monoclonal antibody is a cornerstone therapy for follicular *** anti-CD20 therapy,a potential decrease in CD20 antigen,and therefore a loss of the tumor target might be ***,the incidence and clinical significance of CD20 loss on tumor cells in patients with relapsed or refractory follicular lymphoma are *** study aims to investigate the incidence and outcome of patients with relapsed or refractory follicular lymphoma patients harboring the loss of the tumor target,***:All consecutive adult patients with relapsed or refractory follicular lymphoma referred to the Early Drug Department at gustave roussy were *** main objectives were to assess the incidence and prognosis of the loss in expression of CD20 antigen on the surface of tumor cells on patient ***:Over the study period 2013-2018,131 patients were screened for clinical trials with B-cell malignancies in the early drug department of gustave roussy in ***-four patients presented with relapsed or refractory follicular lymphoma and 32 had tumor biopsies at the time of relapse that were retained for *** median(range)age was 67.5 years(55.3-75.3)and the median number of prior anti-cancer systemic therapies was 3(2-4).At the time of relapse,CD20 expression was positive in 84%of tumors(n=27)and negative in 16%of tumors(n=5).At a median follow-up of 18.3(0.6-83.3)months,CD20 negativity was associated with a poorer prognosis with a median overall survival of 8.9 months(95%CI:2.4-19.1)in comparison to CD20 positive patients(28.3 months,95%CI:25.1-75.3 months,P=0.019).Conclusion:The loss of the tumor target antigen,CD20,occurred in 16%of patients with relapse or refractory follicular *** to confounding factors in patients who received anti-CD20 immunotherapy,it was not possible to formally establish the prognostic significance of CD20 ***,we suggest that a check for CD20 antigen positivity nevertheless

关键词： Follicular lymphoma CD20 tumor antigen anti-CD20 monoclonal antibody cancer drug resistance

CAIRO5 study from a surgical perspective

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatobiliary Surgery and Nutrition 2024年第1期13卷 105-108页

作者： Andrius Meskauskas Maximiliano Gelli gustave roussy Département de AnesthésieChirurgie et InterventionnelVillejuifFrance UniversitéParis-Saclay Gustave RoussyINSERMDynamique des Cellules Tumorales(U-1279)VillejuifFrance

The assessment of resectability,as well as the optimal induction treatment to achieve secondary resectability in patients with colorectal cancer liver metastases(CRLM)remain *** et al.(1)recently presented the results... 详细信息

关键词： Metastatic colorectal cancer(metastatic CRC) liver metastasis immunotherapy

经皮冷冻消融后未完全治疗脊柱转移瘤的MRI早期诊断

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

国际医学放射学杂志 2019年第6期 754-755页

作者： G.Gravel L.Tselikas B,Moulin S.Yevich E.Baudin A.Hakime 计丁心 Department of Interventional Radiology Gustave Roussy Cancer Center

摘要目的评价MRI对于冷冻消融后未完全治疗的脊柱骨质转移(SOM)的检测价值,并提出消融后影像学分类。方法经伦理委员会同意后,回顾性分析2011—2017年间接

关键词：经皮冷冻消融 MRI 早期诊断

Brain macrophage development,diversity and dysregulation in health and disease

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Cellular & Molecular Immunology 2023年第11期20卷 1277-1289页

作者： Aymeric Silvin Jiawen Qian Florent Ginhoux INSERM U1015 Gustave Roussy Cancer CampusVillejuif94800France Shanghai Institute of Immunology Department of Immunology and MicrobiologyShanghai Jiao Tong University School of MedicineShanghai200025China Singapore Immunology Network Agency for ScienceTechnology and ResearchSingapore138648Republic of Singapore Translational Immunology Institute SingHealth Duke-NUS Academic Medical CentreSingapore169856Singapore

Brain macrophages include microglia in the parenchyma,border-associated macrophages in the meningeal-choroid plexus-perivascular space,and monocyte-derived macrophages that infiltrate the brain under various disease *** vast heterogeneity of these cells has been elucidated over the last decade using revolutionary multiomics *** such,we can now start to define these various macrophage populations according to their ontogeny and their diverse functional programs during brain development,homeostasis and disease *** this review,we first outline the critical roles played by brain macrophages during development and healthy *** then discuss how brain macrophages might undergo reprogramming and contribute to neurodegenerative disorders,autoimmune diseases,and ***,we speculate about the most recent and ongoing discoveries that are prompting translational attempts to leverage brain macrophages as prognostic markers or therapeutic targets for diseases that affect the brain.

关键词： Microglia Macrophages Meninges Brain Inflammation

New anticancer drugs in Europe

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 1997年第4期110卷 58-69页

作者： Jean Pierre Armand Department of Medicine Institute Gustave Roussy Villejuif France.

ＮｅｗａｎｔｉｃａｎｃｅｒｄｒｕｇｓｉｎＥｕｒｏｐｅＪｅａｎＰｉｅｒｅＡｒｍａｎｄＦｏｒｔｈｅｎｅａｒｆｕｔｕｒｅ，ｓｙｓｔｅｍｉｃｃｈｅｍｏｔｈｅｒａｐｙｗｉｌｂｅｔｈｅｍａｉｎｓｔａｙｏｆｔｒｅａｔｍｅｎｔｉｎｍ... 详细信息

ＮｅｗａｎｔｉｃａｎｃｅｒｄｒｕｇｓｉｎＥｕｒｏｐｅＪｅａｎＰｉｅｒｅＡｒｍａｎｄＦｏｒｔｈｅｎｅａｒｆｕｔｕｒｅ，ｓｙｓｔｅｍｉｃｃｈｅｍｏｔｈｅｒａｐｙｗｉｌｂｅｔｈｅｍａｉｎｓｔａｙｏｆｔｒｅａｔｍｅｎｔｉｎｍｅｔａｓｔａｔｉｃｃａｎｃｅｒ．Ｉ...

关键词： anticancer